For the doctors' offices, certain platform requirements are important. The instrument needs to be compact to fit into the small avilalable bench space, and it must be flexible to perform different analyses, having a wide parameter menu.
In practice, different disposable cassettes, cartridges or chips with different integrated reagents are used for different analyses, and the instrument actions are specific for each analysis. Often it is desirable to perform several analyses simultaneously in one chip. If blood is used as sample, the analysis must be based on finger prick blood of volumes smaller than 15 microlitres. The reliability and robustness of the results are crucial because there will be no laboratory personnel available to evaluate the result. The instrument must also be simple and safe in use, typically described by the US CLiA-waived approval requirements [3] . The test procedure should include a maximum of three handling steps; "add sample -activate -read result". In addition, in order to get the results within the time frame of a typical consultation, the results should be available within a few minutes. All these requirements have in some cases been met for protein analyses, such as in the Afinion platform [4], but diagnostics and screening based on nucleic acid analyses that include an amplification step is normally slower, more than 30-60 minutes.
In this paper we will first describe the successful commercial platform for blood protein analyses, the Afinion platform from Axis-Shield. We also give an overview of disease related protein markers in blood, and show how their relevant concentrations for diagnostics vary over ten orders of magnitude. For a broader panel of diagnostics in the doctors' offices in the future, micro fluidic chips and new sensitive biosensors will be crucial.
Then we will move to nucleic acid based POC analyses and an example of a prototype platform for nucleic acid analysis used for multiplex HPV virus diagnostics from cervical smear specimen.
In order to develop a new diagnostic platform, not only the instrument with pumping mechanisms, heaters and biosensor read-out must be created, but also the disposable cartridges or chips. These chips need biological surface layers and stored dry and wet reagents, and sometimes sensitive biosensors may be included on-chip. In the last section we describe how the challenges of manufacturability of systems that combines very different technologies can be approached.
II. POC DIAGNOSTICS BASED ON PROTEIN ANALYSIS
For protein based analyses, there are already some point of-care in-vitro diagnostic products on the marked. These are in general not based on microfluidics or nanotechnology sensors, but larger, disposable polymer cartridges that have integrated reagents and wash buffers. For each new test to be performed, a new cartridge is opened, the patient sample is sucked into the cartridge and the cartridge is inserted into the instrument that performs the analysis and shows the result in a panel.
One example is the Axis-Shield platform Afinion (see In table 2 we list some more proteins relevant for point of-care diagnosis and the diseases related to those proteins.
In figure 2 the concentration levels of the proteins are plotted. The concentration ranges relevant for diagnostics vary from just a few protein molecules per sample (e.g. 10. 18 giL) to relatively high concentrations (up to giL quantities).
New and more sensitive sensing principles will be needed for the low concentration proteins. A review of recent advances in immunoanalytical systems can be found in [5] , where different optical, electrochemical, magnetic or mechanical protein detection methods are described. The Verigene ® System by Nanosphere [5] is an example of new systems that meets the challenge of detecting nucleic acids and proteins with a very high sensitivity. The system utilizes patented gold nanoparticle technology to obtain detectable signals from a few molecules.
III. POC DIAGNOSTICS BASED ON NUCELIC ACID ANALYSIS
At present, POC testing for nucleic acid strands is most relevant for infectious diseases. In the future, also personalized medicine will be a large marked. While more sensitive detection techniques, like Verigene' s, will open for direct nucleic acid detection, the common procedure is to create millions of copies of the marker DNA sequence before detection. This is done by enzymatic amplification techniques, like polymerase chain reactions (PCR). The amplification requires purified nucleic acids to avoid inhibition of the reactions. Due to the complexity and diversity of patient samples and the number of steps involved in nucleic acid extraction, the main hurdle of POC DNA analysis is the sample preparation [7] . POC systems based on microfluidic chips are thus mainly on the patent and prototype stage, with exceptions such as Cepheid' s GeneXpert cassette [8] .
In the European funded project MicroActive a new prototype platform for automated mRNA based diagnosis was established [9] . In the project, the developed system was tested successfully for the "proof-of-principle" detection of biomarkers indicative of cervical pre-cancer. 
IV. MANUFACTURING TECHNOLOGIES
The manufacturability and cost of the platform instrument and disposable chips is of crucial importance for a potential commercial product. In particular, the microfluidic chip manufacturing will involve micro-and nanostructuring of polymers combined with microchannel surface treatment supporting both liquid control and biochemical reactions. 
